Enablement Requirement

The statutory standard under 35 U.S.C. §112(a) requiring a patent specification to teach a person skilled in the art how to make and use the claimed invention

Amgen Inc. v. Sanofi
  1. Amgen Inc. v. Sanofi
  2. Jurisdiction: United States (May 18, 2023)
  3. Original Case: Amgen Inc. v. Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S. LLC
  4. Victims<![CDATA[None]]>Defendants<![CDATA[Sanofi]]><![CDATA[Aventisub LLC]]><![CDATA[Regeneron Pharmaceuticals Inc.]]><![CDATA[Sanofi-Aventis U.S. LLC]]>Plaintiffs<![CDATA[Amgen Inc.]]>Investigators<![CDATA[None]]>Prosecutors<![CDATA[None]]>Defense Attorneys<![CDATA[Paul D. Clement]]>Plaintiff Attorneys<![CDATA[Jeffrey A. Lamken]]>Judges<![CDATA[Neil M. Gorsuch]]><![CDATA[John G. Roberts]]><![CDATA[Clarence Thomas]]><![CDATA[Samuel A. Alito]]><![CDATA[Sonia Sotomayor]]><![CDATA[Elena Kagan]]><![CDATA[Brett M. Kavanaugh]]><![CDATA[Amy Coney Barrett]]><![CDATA[Ketanji Brown Jackson]]>Institutions<![CDATA[United States Supreme Court]]><![CDATA[Amgen Inc.]]><![CDATA[Sanofi]]><![CDATA[Regeneron Pharmaceuticals Inc.]]><![CDATA[United States Court of Appeals for the Federal Circuit]]>
  5. Case Tags: Patent Law;Enablement Requirement;Biotechnology Patents;Supreme Court Decisions